G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cash & Cash Equivalents
kr135.8m
CAGR 3-Years
48%
CAGR 5-Years
72%
CAGR 10-Years
41%
AddLife AB
STO:ALIF B
Cash & Cash Equivalents
kr272m
CAGR 3-Years
8%
CAGR 5-Years
35%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash & Cash Equivalents
kr861m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cash & Cash Equivalents
kr370m
CAGR 3-Years
1%
CAGR 5-Years
23%
CAGR 10-Years
17%
MedCap AB (publ)
STO:MCAP
Cash & Cash Equivalents
kr287.7m
CAGR 3-Years
29%
CAGR 5-Years
76%
CAGR 10-Years
15%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash & Cash Equivalents
kr7.1m
CAGR 3-Years
5%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
135.8m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cash & Cash Equivalents amounts to 135.8m SEK.

What is Genovis AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
41%

Over the last year, the Cash & Cash Equivalents growth was 19%. The average annual Cash & Cash Equivalents growth rates for Genovis AB have been 48% over the past three years , 72% over the past five years , and 41% over the past ten years .

Back to Top